ArtechMed

About ArtechMed

Based in Shanghai, ArtechMed is a privately held medical technology company established in 2017, focusing on the surgical device market. The firm is dedicated to creating and manufacturing medical equipment for the minimally invasive interventional treatment of atrial fibrillation. The company's team is described as having extensive experience, averaging over 15 years, in cardiovascular intervention, cardiac electrophysiology, and cryoablation.

The company operates in a significant market, as China has over 10 million patients with atrial fibrillation, a condition that substantially increases the risk of stroke. ArtechMed's business model centers on the development and sale of advanced medical devices to healthcare providers. The company is currently generating revenue and has progressed through multiple funding rounds to support its growth, from product development and clinical trials to full commercialization. Since its inception, ArtechMed has raised a total of $14.9 million from various investors, including Jinan International Medical Center Industrial Development, Y.R. Delta Fund, Huangpu Biomedical Industry Investment Fund, and Shanghai Zhangjiang Science & Technology Venture Capital.

ArtechMed's product portfolio is centered on addressing atrial fibrillation through less invasive methods. Key technologies include a new generation of Cryoballoon Ablation (CBA) and Pulsed Field Ablation (PFA) systems. PFA technology, in particular, has gained attention for its high ablation efficiency and tissue selectivity, which reduces risks compared to traditional ablation methods. Published clinical results have shown promising success rates for the PFA technique. In addition to these core products, the company's website also lists a broader range of medical devices across urology, patient care, endoscopic surgery, and physical therapy, indicating a diversified product strategy aimed at equipping medical practitioners with a comprehensive suite of tools.